Fermagate(Fermagate) - 药物靶点：Phosphates_在研适应症：低磷血症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Alpharen、Macrosorb MD

靶点

Phosphates

作用方式

调节剂

作用机制

Phosphates 调节剂(磷酸盐调节剂)

治疗领域

内分泌与代谢疾病

在研适应症

低磷血症

非在研适应症

高磷血症终末期肾脏病

原研机构

Ineos Healthcare Ltd.

在研机构

Prolor Biotech Ltd.

非在研机构

Ineos Healthcare Ltd.OPKO Renal LLC

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式CH8FeMgO10

InChIKeyOFCDMSYSINJNMW-UHFFFAOYSA-F

CAS号119175-48-3

查看全部结构式(2)

关联

8

项与 Fermagate 相关的临床试验

EUCTR2008-004730-25-BE

/ Not yet recruitingN/A

An open, randomised, controlled, parallel group, Phase III study to investigate the safety and efficacy of fermagate and sevelamer hydrochloride in haemodialysis patients with hyperphosphataemia.

开始日期2009-09-09

申办/合作机构

Ineos Healthcare Ltd.

NCT00844662

/ Terminated临床3期

An Open, Randomised, Controlled, Parallel Group, Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride in Haemodialysis Patients With Hyperphosphataemia

Magnesium iron hydroxycarbonate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb.
The purpose of this study is to assess the efficacy of magnesium iron hydroxycarbonate in subjects requiring haemodialysis, compared with a marketed phosphate binder, sevelamer hydrochloride.

开始日期2009-07-01

申办/合作机构

Ineos Healthcare Ltd.

NCT00436683

/ Completed临床2期

An Open Label, Dose-Ranging Study to Establish the Tolerability of Magnesium Iron Hydroxycarbonate in Haemodialysis Subjects With Hyperphosphataemia.

Magnesium iron hydroxycarbonate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb.
The purpose of this study is to determine how well a range of different doses of fermagate are tolerated by the subjects in the trial.

开始日期2007-02-01

申办/合作机构

Ineos Healthcare Ltd.

100 项与 Fermagate 相关的临床结果

登录后查看更多信息

100 项与 Fermagate 相关的转化医学

登录后查看更多信息

100 项与 Fermagate 相关的专利（医药）

登录后查看更多信息

14

项与 Fermagate 相关的文献（医药）

2021-09-01·International Urology and Nephrology4区 · 医学

Using iron-based phosphate binders in phosphate reduction and anemia improvement in patients receiving dialysis: a meta-analysis of randomized controlled trials

4区 · 医学

Article

作者: Zhu, Yan ; Rao, Jinlan ; Liao, Xueling ; Li, Wei ; Xue, Chao ; Ou, Jihong

PURPOSEA study was conducted to determine whether iron-based phosphate binders (IBPBs) need to be preferred for hyperphosphatemia and anemia management in patients on dialysis.METHODSFor this meta-analysis, we searched PubMed, Embase, and Cochrane Central Register of Controlled Trials for randomized controlled trials that evaluated the efficacy and safety of IBPBs in decreasing phosphate and correcting anemia in dialysis patients.RESULTSNineteen trials comprising 4719 participants were included. Compared with placebo, serum phosphate decreased significantly after treatment with ferric citrate (FC), fermagate (one study), and SBR759 (one study). Hemoglobin increased significantly after treatment with FC and sucroferric oxyhydroxide (PA21). In addition, FC and PA21 reduced serum intact parathyroid hormone (iPTH) and increased ferritin and transferrin saturation, but SBR759 did not. Compared with active treatment, the non-inferiority of IBPBs in reducing serum phosphate and iPTH was demonstrated. FC significantly improved serum hemoglobin and iron-related parameters and decreased the use of intravenous iron and erythropoiesis-stimulating agent, whereas PA21 did not increase serum hemoglobin level. The incidences of infection and hospitalization were similar between the two groups, with FC having a higher risk of diarrhea than the placebo and active treatments.CONCLUSIONFC was associated with the control of hyperphosphatemia and the improvement of anemia. However, PA21 did not show superiority for alleviating anemia compared with the active treatment. Other IBPBs, such as fermagate and SBR759, remained poorly understood due to the limited number of studies. Further trials are required to assess the effect of IBPBs on the risk of cardiovascular events and all-cause mortality.

2017-03-23·The Journal of Physical Chemistry C

Carbonate–Hydrogenocarbonate Coexistence and Dynamics in Layered Double Hydroxides

作者: Carteret, Cédric ; Durand, Pierrick ; Kervern, Gwendal ; Di Bitetto, Arnaud ; André, Erwan

Carbonated layered double hydroxides were fully characterized by vibrational spectroscopies, powder x-ray diffraction and solid-state NMR tuning the cations, the layer charge d., and the preparation method to get original structural and dynamical features within the materials.It clearly appears that carbonate and hydrogenocarbonate coexist in the same interlayer after contact with air and also that the hydrogenocarbonate quantity is correlated to the M^II/M^III molar ratio constituting a strong pH probe of the interlayer space.Likewise, these two species are involved in an exchange process with atm. CO₂, and hydrogenocarbonate proves to be the key parameter of exchange kinetics.These crucial results, extended to various cationic couples, could lead to new alternatives for CO₂ storage.

2015-01-02·Renal Failure4区 · 医学

Effects and safety of iron-based phosphate binders in dialysis patients: a systematic review and meta-analysis

4区 · 医学

ReviewOA

作者: Jing Sun ; Rong Wang ; Xin-Shuang Yu ; Xiao-Wei Yang ; Chun-Juan Zhai

AIMTo assess the effects and safety of iron-based phosphate binders in adult patients receiving dialysis.METHODSWe electronically searched MEDLINE, EMBASE, CENTRAL, and CBM for randomized controlled trials about iron-based phosphate binders in adult dialysis patients. Study quality was assessed using the criteria outlined in the Cochrane Handbook for Systematic Reviews of intervention. Meta-analysis was conducted by RevMan 5.3.RESULTSEight studies with 2018 participants were eligible for our meta-analysis. Iron-based phosphate binders were superior to placebo (MD = -2.43 mg/dL, 95% CI: -3.18 to -1.68, p < 0.00001) and as efficient as sevelamer (MD = 0.04 mg/dL, 95% CI: -0.29 to 0.36, p = 0.83) in reducing serum phosphorus in dialysis patients. No significant differences were found in all adverse events (OR = 1.30, 95% CI: 0.77 to 2.20, p = 0.32) between iron-based phosphate binders and placebo. Iron-based phosphate binders were associated with significant higher serum iron (MD = 9.39 ng/mL, 95% CI 1.48 to 17.30, p = 0.02), higher serum transferring saturation (MD = 6.29%, 95% CI 2.72 to 9.87, p = 0.0006) and lower serum total iron binding capacity (MD = -23.13 µg/dL, 95% CI -35.69 to -10.58, p = 0.0003) in comparison to placebo.CONCLUSIONIron-based phosphate binders are as effective as sevelamer and well tolerated for hyperphosphatemia in dialysis patients. Iron-based phosphate binders appear to have a beneficial effect on renal anemia in patients receiving dialysis. Therefore, iron-based phosphate binders may represent a new treatment option for dialysis patients.

100 项与 Fermagate 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Fermagate	-	-

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
终末期肾脏病	药物发现	斯洛伐克	Ineos Healthcare Ltd.	2009-07-01
终末期肾脏病	药物发现	英国	Ineos Healthcare Ltd.	2009-07-01
终末期肾脏病	药物发现	匈牙利	Ineos Healthcare Ltd.	2009-07-01
终末期肾脏病	药物发现	保加利亚	Ineos Healthcare Ltd.	2009-07-01
终末期肾脏病	药物发现	意大利	Ineos Healthcare Ltd.	2009-07-01
终末期肾脏病	药物发现	捷克	Ineos Healthcare Ltd.	2009-07-01
终末期肾脏病	药物发现	墨西哥	Ineos Healthcare Ltd.	2009-07-01
终末期肾脏病	药物发现	巴西	Ineos Healthcare Ltd.	2009-07-01
终末期肾脏病	药物发现	以色列	Ineos Healthcare Ltd.	2009-07-01
终末期肾脏病	药物发现	爱沙尼亚	Ineos Healthcare Ltd.	2009-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASN2018	N/A	慢性肾病	23	Fermagate	餘膚壓製鏇簾鬱窪憲壓(衊鏇醖蓋齋艱鹽製醖顧) = 餘築選獵範範願製蓋積製獵觸窪廠醖製齋廠餘 (鬱襯構鹽廠簾壓獵糧繭, 79%/65%inCONvs.35%FER(0.75%P)and13%FER(0.5-1%P) ~ p<0.001)	积极	2018-10-23